Rigel Pharmaceuticals (RIGL) Competitors

Rigel Pharmaceuticals (NASDAQ:RIGL) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Is RIGL or INVA more profitable?

Innoviva has a net margin of 18.31% compared to Rigel Pharmaceuticals' net margin of 2.46%. Innoviva's return on equity of 20.84% beat Rigel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	2.46%	-14.80%	3.03%
Innoviva	18.31%	20.84%	11.38%

Does the MarketBeat Community prefer RIGL or INVA?

Rigel Pharmaceuticals received 162 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 68.98% of users gave Rigel Pharmaceuticals an outperform vote while only 57.55% of users gave Innoviva an outperform vote.

Company	Underperform	Outperform
Rigel Pharmaceuticals	Outperform Votes 467 68.98%	Underperform Votes 210 31.02%
Innoviva	Outperform Votes 305 57.55%	Underperform Votes 225 42.45%

Which has more volatility & risk, RIGL or INVA?

Rigel Pharmaceuticals has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in RIGL or INVA?

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 9.0% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 1.7% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has preferable earnings & valuation, RIGL or INVA?

Innoviva has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$179.28M	1.64	-$25.09M	$0.94	17.54
Innoviva	$358.71M	3.16	$179.72M	$0.19	95.21

Do analysts prefer RIGL or INVA?

Rigel Pharmaceuticals currently has a consensus price target of $36.80, suggesting a potential upside of 123.17%. Innoviva has a consensus price target of $55.00, suggesting a potential upside of 204.04%. Given Innoviva's stronger consensus rating and higher probable upside, analysts clearly believe Innoviva is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Innoviva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to RIGL or INVA?

In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 5 articles in the media. Rigel Pharmaceuticals' average media sentiment score of 1.65 beat Innoviva's score of 1.56 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Innoviva	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Innoviva beats Rigel Pharmaceuticals on 9 of the 16 factors compared between the two stocks.